Randomized Trial of Interleukin-6 Receptor Inhibition in Patients With Acute ST-Segment Elevation Myocardial Infarction

Broch, Kaspar; Anstensrud, Anne Kristine; Woxholt, Sindre; Sharma, Kapil; Tøllefsen, Ingvild Maria; Bendz, Bjørn; Aakhus, Svend; Ueland, Thor; Amundsen, Brage H.; Damås, Jan Kristian; Berg, Erlend Sturle; Bjørkelund, Elisabeth; Bendz, Christina; Hopp, Einar; Kleveland, Ola; Stensæth, Knut Haakon; Opdahl, Anders; Kløw, Nils‐Einar; Seljeflot, Ingebjørg; Andersen, Geir Øystein; Wiseth, Rune; Aukrust, Pål; Gullestad, Lars

doi:10.1016/j.jacc.2021.02.049

Cited by 194 publications

(147 citation statements)

References 26 publications

Supporting

Mentioning

141

Contrasting

Unclassified

Order By: Relevance

“…Additionally, Kleveland et al (Kleveland et al, 2016) showed that tocilizumab inhibited the myocardial inflammatory reaction in patients with non-ST-elevation MI, reduced hs-CRP levels and decreased troponin T release. Moreover, Broch et al (Broch et al, 2021) demonstrated that the early administration of IL-6 receptor inhibitor such as tocilizumab on patients with non-ST-elevation MI within 6 h of symptom onset could reduce myocardial necrosis and infarct size. Also, tocilizumab has been well tolerated and has no significant safety concerns.…”

Section: In Heart Failurementioning

confidence: 99%

Interleukin-6: A Novel Target for Cardio-Cerebrovascular Diseases

Luo

Liang

et al. 2021

Front. Pharmacol.

View full text Add to dashboard Cite

Cardio-Cerebrovascular Disease is a collective term for cardiovascular disease and cerebrovascular disease, being a serious threat to human health. A growing number of studies have proved that the content of inflammatory factors or mediators determines the stability of vascular plaque and the incidence of cardio-cerebrovascular event, and involves in the process of Cardio-Cerebrovascular Diseases. Interleukin-6 is a widely used cytokine that causes inflammation and oxidative stress, which would further result in cardiac and cerebral injury. The increased expression of interleukin-6 is closely related to atherosclerosis, myocardial infarction, heart failure and ischemic stroke. It is a key risk factor for these diseases by triggering inflammatory reaction and inducing other molecules release. Therefore, interleukin-6 may become a potential target for Cardio-Cerebrovascular Diseases in the future. This paper is aimed to discuss the expression changes and pathological mechanisms of interleukin-6 in Cardio-Cerebrovascular Diseases, and to provide a novel strategy for the prevention and treatment of Cardio-Cerebrovascular Diseases.

show abstract

Section: In Heart Failurementioning

confidence: 99%

Interleukin-6: A Novel Target for Cardio-Cerebrovascular Diseases

Luo

Liang

et al. 2021

Front. Pharmacol.

View full text Add to dashboard Cite

show abstract

“…In addition, reduced myocardial injury was seen in patients who were resuscitated after cardiac arrest 215 . Notably, in patients with STEMI, intravenous tocilizumab during PCI reduced microvascular obstruction and improved the salvage index on MRI 3–7 days after the procedure, supporting the notion that inflammatory microembolization is a contributing factor in microvascular obstruction 216 . However, the protection by tocilizumab was significant but small in magnitude, and no outcome data for tocilizumab in patients with NSTEMI or STEMI are yet available.…”

Section: Prevention and Treatmentmentioning

confidence: 61%

A fresh look at coronary microembolization

Kleinbongard

Heusch

2021

Nat Rev Cardiol

View full text Add to dashboard Cite

“…In summary, there is growing evidence that reducing inflammation can lower incident CVD but off-target effects, in particular infection/sepsis, are a concern. In contrast, we do not have convincing evidence yet that anti-inflammatory therapies lead to sustained reduction in T2D and metabolic disease (72,73,(75)(76)(77)84).…”

Section: Pharmacological Evidence Supporting a Role Of Inflammation In T2d And Cvdmentioning

confidence: 70%

Obesity and Cardiovascular Disease: The Emerging Role of Inflammation

Khafagy

Dash

2021

Front. Cardiovasc. Med.

View full text Add to dashboard Cite

Obesity is a growing public health challenge across the globe. It is associated with increased morbidity and mortality. Cardiovascular disease (CVD) is the leading cause of mortality for people with obesity. Current strategies to reduce CVD are largely focused on addressing traditional risk factors such as dyslipidemia, type 2 diabetes (T2D) and hypertension. Although this approach is proven to reduce CVD, substantial residual risk remains for people with obesity. This necessitates a better understanding of the etiology of CVD in people with obesity and alternate therapeutic approaches. Reducing inflammation may be one such strategy. A wealth of animal and human data indicates that obesity is associated with adipose tissue and systemic inflammation. Inflammation is a known contributor to CVD in humans and can be successfully targeted to reduce CVD. Here we will review the etiology and pathogenesis of inflammation in obesity associated metabolic disease as well as CVD. We will review to what extent these associations are causal based on human genetic studies and pharmacological studies. The available data suggests that anti-inflammatory treatments can be used to reduce CVD, but off-target effects such as increased infection have precluded its broad therapeutic application to date. The role of anti-inflammatory therapies in improving glycaemia and metabolic parameters is less established. A number of clinical trials are currently ongoing which are evaluating anti-inflammatory agents to lower CVD. These studies will further clarify whether anti-inflammatory agents can safely reduce CVD.

show abstract

Randomized Trial of Interleukin-6 Receptor Inhibition in Patients With Acute ST-Segment Elevation Myocardial Infarction

Cited by 194 publications

References 26 publications

Interleukin-6: A Novel Target for Cardio-Cerebrovascular Diseases

Interleukin-6: A Novel Target for Cardio-Cerebrovascular Diseases

A fresh look at coronary microembolization

Obesity and Cardiovascular Disease: The Emerging Role of Inflammation

Contact Info

Product

Resources

About